Skip to Main Navigation
Skip to Page Content

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/28760

Transgenic model evaluation II (Glycidol): Target Organs and Levels of Evidence for GMM-13

Toxicology and Carcinogenesis Study of Glycidol (CASRN 556-52-5) in Genetically Modified Haploinsufficient p16Ink4a/p19Arf Mice (Gavage Study)

Chemical (Study Title)
CASRN
Peer Review Date Route/Exposure Levels Study Laboratory
Transgenic model evaluation II (Glycidol)
556-52-5
08/28/2006 Gavage
0, 25, 50, 100, or 200 mg/kg
Battelle Columbus Laboratory

Levels of evidence information for Carcinogenesis and Genetic Toxicology Studies of Glycidol in Haploinsufficient p16Ink4a/p19Arf Mice
  Male Haploinsufficient p16Ink4a/p19Arf Mice Female Haploinsufficient p16Ink4a/p19Arf Mice
  40 Weeks 40 Weeks
Levels of Evidence Clear Evidence Some Evidence
May have been related None
  • Forestomach: squamous cell papilloma 0/15 0/15 0/15 1/15 3/15
Neoplastic Lesions
  • All organs: histiocytic sarcoma 2/15 6/15 9/15 5/15 11/15
  • Lung: alveolar/bronchiolar adenoma 1/15 0/15 2/15 7/15 3/15
  • Lung: alveolar/bronchiolar adenoma 0/15 1/15 0/15 1/15 4/15
Non-Neoplastic Lesions
  • Forestomach: epithelium hyperplasia
  • Brain: neuronopathy
  • Forestomach: epithelium hyperplasia
  • Brain: neuronopathy